Goldman Sachs Group Inc. Has $27.04 Million Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Goldman Sachs Group Inc. lessened its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 19.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 733,546 shares of the company’s stock after selling 179,405 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.27% of Twist Bioscience worth $27,039,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of TWST. Artisan Partners Limited Partnership increased its position in Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after buying an additional 1,961,621 shares during the last quarter. Invesco Ltd. increased its position in Twist Bioscience by 1,496.2% during the third quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock worth $16,836,000 after buying an additional 778,944 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of Twist Bioscience by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock worth $265,881,000 after acquiring an additional 427,274 shares during the period. AEGON ASSET MANAGEMENT UK Plc bought a new stake in shares of Twist Bioscience during the fourth quarter worth approximately $11,956,000. Finally, Norges Bank bought a new stake in shares of Twist Bioscience during the fourth quarter worth approximately $10,766,000.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TWST. Evercore ISI boosted their price objective on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. TD Cowen boosted their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Scotiabank boosted their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, May 6th. Guggenheim assumed coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective for the company. Finally, Robert W. Baird boosted their price target on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $46.63.

Twist Bioscience Trading Up 4.6 %

Shares of TWST stock opened at $50.97 on Monday. The stock has a market cap of $2.97 billion, a P/E ratio of -15.17 and a beta of 1.78. The stock has a 50 day simple moving average of $41.89 and a 200 day simple moving average of $37.69. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $55.26.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The firm had revenue of $75.30 million during the quarter, compared to analysts’ expectations of $70.70 million. During the same period in the prior year, the company earned ($1.06) earnings per share. The company’s quarterly revenue was up 25.1% on a year-over-year basis. Analysts forecast that Twist Bioscience Co. will post -3.08 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 2,408 shares of the company’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total transaction of $123,602.64. Following the completion of the sale, the chief executive officer now directly owns 507,578 shares in the company, valued at $26,053,978.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Emily M. Leproust sold 1,132 shares of the company’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the completion of the transaction, the chief executive officer now directly owns 514,149 shares in the company, valued at $16,833,238.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 2,408 shares of the company’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total transaction of $123,602.64. Following the transaction, the chief executive officer now owns 507,578 shares of the company’s stock, valued at $26,053,978.74. The disclosure for this sale can be found here. Insiders sold 17,163 shares of company stock worth $666,151 over the last three months. Insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.